Relay Therapeutics (RLAY) Expected to Announce Earnings on Monday

Relay Therapeutics (NASDAQ:RLAY) is expected to release its Q1 2026 results after the market closes on Monday, May 4th. Analysts expect Relay Therapeutics to post earnings of ($0.35) per share and revenue of $4.2250 million for the quarter. Interested persons can find conference call details on the company’s upcoming Q1 2026 earning report page for the latest details on the call scheduled for Tuesday, May 5, 2026 at 4:00 PM ET.

Relay Therapeutics (NASDAQ:RLAY) last announced its quarterly earnings data on Thursday, February 26th. The company reported ($0.32) earnings per share for the quarter, topping the consensus estimate of ($0.38) by $0.06. The firm had revenue of $7.00 million for the quarter, compared to the consensus estimate of $4.34 million. On average, analysts expect Relay Therapeutics to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Relay Therapeutics Stock Performance

Shares of NASDAQ:RLAY opened at $15.13 on Monday. The stock has a market capitalization of $2.70 billion, a P/E ratio of -9.34 and a beta of 1.57. Relay Therapeutics has a 1-year low of $2.67 and a 1-year high of $17.32. The business has a 50-day moving average price of $11.52 and a two-hundred day moving average price of $8.98.

Insider Transactions at Relay Therapeutics

In other news, insider Donald A. Bergstrom sold 18,895 shares of the business’s stock in a transaction dated Tuesday, January 27th. The stock was sold at an average price of $7.62, for a total transaction of $143,979.90. Following the completion of the transaction, the insider directly owned 422,733 shares in the company, valued at approximately $3,221,225.46. The trade was a 4.28% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Peter Rahmer sold 11,684 shares of the business’s stock in a transaction dated Tuesday, January 27th. The stock was sold at an average price of $7.62, for a total value of $89,032.08. Following the transaction, the insider owned 277,964 shares of the company’s stock, valued at $2,118,085.68. The trade was a 4.03% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders sold 69,651 shares of company stock worth $644,279. 4.32% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Relay Therapeutics

Institutional investors have recently modified their holdings of the business. Invesco Ltd. increased its stake in Relay Therapeutics by 139.6% during the 4th quarter. Invesco Ltd. now owns 865,481 shares of the company’s stock worth $7,322,000 after purchasing an additional 504,291 shares in the last quarter. EP Wealth Advisors LLC bought a new stake in Relay Therapeutics during the 4th quarter worth approximately $106,000. XTX Topco Ltd bought a new stake in Relay Therapeutics during the 4th quarter worth approximately $1,332,000. VARCOV Co. bought a new stake in Relay Therapeutics during the 4th quarter worth approximately $248,000. Finally, Tudor Investment Corp ET AL increased its stake in Relay Therapeutics by 10.1% during the 4th quarter. Tudor Investment Corp ET AL now owns 84,163 shares of the company’s stock worth $712,000 after purchasing an additional 7,717 shares in the last quarter. Institutional investors own 96.98% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages have weighed in on RLAY. Wells Fargo & Company boosted their price objective on Relay Therapeutics from $15.00 to $17.00 and gave the stock an “overweight” rating in a report on Tuesday, March 17th. Weiss Ratings reissued a “sell (d-)” rating on shares of Relay Therapeutics in a report on Wednesday, April 8th. Citizens Jmp boosted their target price on Relay Therapeutics from $15.00 to $17.00 and gave the stock a “market outperform” rating in a research report on Tuesday, March 17th. JonesTrading started coverage on Relay Therapeutics in a research report on Tuesday, April 14th. They set a “hold” rating and a $18.00 target price for the company. Finally, Guggenheim boosted their target price on Relay Therapeutics from $15.00 to $22.00 and gave the stock a “buy” rating in a research report on Friday, March 13th. One equities research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $18.38.

About Relay Therapeutics

Relay Therapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of precision therapies for oncology. Headquartered in Cambridge, Massachusetts, the company was founded in 2016 with the goal of targeting dynamic protein motion using an integrated scientific platform. Relay Therapeutics leverages computational modeling, structural biology, and experimental validation to identify small-molecule drug candidates that modulate the behavior of disease-associated proteins.

The company’s core business activity centers on its proprietary drug-discovery engine, which combines high-performance computing—including molecular dynamics simulations—with advanced experimental techniques such as cryo-electron microscopy and biophysical screening.